Ivo A. Olivotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ivo A. Olivotto has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Boon Chua
Radiation Therapy and Systemic Therapy Programs, British Columbia Cancer Agency, Vancouver Island Center, Victoria, British Columbia, Canada
4 shared publicationsCaroline H. Speers
From the Breast Cancer Outcomes Unit, Radiation, Medical, and Population and Preventive Oncology Programs, the Vancouver Island, Vancouver, and Fraser Valley Centres of the British Columbia Cancer Agency; the University of British Columbia, Victoria, Vancouver, and Surrey, British Columbia, Canada; and The University of Texas Health Sciences Center, San Antonio, TX
2 shared publicationsJoseph Ragaz
2 shared publicationsLisa Kan
2 shared publicationsWinkle Kwan
From the British Columbia Cancer Agency–Vancouver Island Centre, Vancouver Centre, Centre for the Southern Interior; and Fraser Valley Centre, Radiation Therapy Program, Systemic Therapy Program, and Breast Cancer Outcomes Unit, University of British Columbia; and the Department of Mathematics and Statistics, University of Victoria, British Columbia, Canada
2 shared publicationsA. Goldrick
Breast Cancer Outcomes Unit, BC Cancer Agency, Vancouver, British Columbia
1 shared publication
Latest Publications
- Open Access
- 27 January 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 35
Investigation of variability in image acquisition and contouring during 3D ultrasound guidance for partial breast irradiation
Three-dimensional ultrasound (3DUS) at simulation compared to 3DUS at treatment is an image guidance option for partial breast irradiation (PBI). This study assessed if user dependence in acquiring and contouring 3DUS (operator variability) contributed to variation in seroma shifts calculated for breast IGRT.
- 27 January 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 35
Open AccessInvestigation of variability in image acquisition and contouring during 3D ultrasound guidance for partial breast irradiation
Three-dimensional ultrasound (3DUS) at simulation compared to 3DUS at treatment is an image guidance option for partial breast irradiation (PBI). This study assessed if user dependence in acquiring and contouring 3DUS (operator variability) contributed to variation in seroma shifts calculated for breast IGRT.
- 1 January 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (1) , 16-23
Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy
Purpose: To determine the interval from breast-conserving surgery (BCS) to radiation therapy (RT) that affects local control or survival. Patients and Methods: The 10-year Kaplan-Meier (KM) local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and breast cancer–specific survival (BCSS) were computed for 6,428 women who had T1 to 2, N0 to 1, M0 breast cancer that was diagnosed in British Columbia between 1989 and 2003, and who were treated with BCS and RT without chemotherapy. Intervals from BCS to RT were grouped by weeks as follows: ≤ 4 (n = 83), greater than 4 to 8 (n = 2,288; reference group); greater than 8 to 12 (n = 2,606); greater than 12 to 16 (n = 961); greater than 16 to 20 (n = 358); and greater than 20 weeks (n = 132). Cox proportional hazards models and matching were used to control for confounding variables. Results: The median follow-up time was 7.5 years. The 10-year KM outcomes were as follows: LRFS, 95.4%; DRFS, 90.5%; and BCSS, 92.5%. Compared with the greater than 4 to 8 weeks group, hazard ratios (HR) were not significantly different for any outcome among patients who were treated up to 20 weeks after BCS. However, LRFS (hazard ratio [HR], 2.00; P = .15), DRFS (HR, 1.86; P = .02) and BCSS (HR, 2.15; P = .009) were inferior for women with BCS-to-RT intervals greater than 20 weeks compared with those greater than 4 to 8 weeks. The matched analysis yielded similar results. Conclusion: Outcomes were statistically similar for BCS-to-RT intervals up to 20 weeks, but they were inferior for intervals beyond 20 weeks. Time can be reasonably allowed for the breast to heal and for patients to consider treatment options, but RT should start within 20 weeks of BCS.
- 1 January 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (1) , 16-23
Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy
Purpose: To determine the interval from breast-conserving surgery (BCS) to radiation therapy (RT) that affects local control or survival. Patients and Methods: The 10-year Kaplan-Meier (KM) local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and breast cancer–specific survival (BCSS) were computed for 6,428 women who had T1 to 2, N0 to 1, M0 breast cancer that was diagnosed in British Columbia between 1989 and 2003, and who were treated with BCS and RT without chemotherapy. Intervals from BCS to RT were grouped by weeks as follows: ≤ 4 (n = 83), greater than 4 to 8 (n = 2,288; reference group); greater than 8 to 12 (n = 2,606); greater than 12 to 16 (n = 961); greater than 16 to 20 (n = 358); and greater than 20 weeks (n = 132). Cox proportional hazards models and matching were used to control for confounding variables. Results: The median follow-up time was 7.5 years. The 10-year KM outcomes were as follows: LRFS, 95.4%; DRFS, 90.5%; and BCSS, 92.5%. Compared with the greater than 4 to 8 weeks group, hazard ratios (HR) were not significantly different for any outcome among patients who were treated up to 20 weeks after BCS. However, LRFS (hazard ratio [HR], 2.00; P = .15), DRFS (HR, 1.86; P = .02) and BCSS (HR, 2.15; P = .009) were inferior for women with BCS-to-RT intervals greater than 20 weeks compared with those greater than 4 to 8 weeks. The matched analysis yielded similar results. Conclusion: Outcomes were statistically similar for BCS-to-RT intervals up to 20 weeks, but they were inferior for intervals beyond 20 weeks. Time can be reasonably allowed for the breast to heal and for patients to consider treatment options, but RT should start within 20 weeks of BCS.
- Open Access
- 1 December 2007
- Published by MDPI AG in Current Oncology
- Vol. 14 (6) , 227-233
Anemia is a Common but Neglected Complication of Adjuvant Chemotherapy for Early Breast Cancer
In this study, we set out to determine the frequency and severity of anemia and the corrective interventions used during adjuvant chemotherapy for breast cancer. We conducted a retrospective electronic chart review of 702 patients who received adjuvant breast cancer chemotherapy at four BC Cancer Agency centres in 2002 and 2003. For these patients, we recorded the initial hemoglobin reading and the date of the first hemoglobin reading in the ranges 110–119 g/L, 100– 109 g/L, 90–99 g/L, and <90 g/L. We also recorded any discussion about, or delivery of, interventions for anemia [transfusion, epoetin (EPO) or both]. Median age of the study population was 51 years, and it varied with chemotherapy type. Among the patients, 12% had a hemoglobin reading <120 g/L before the start of chemotherapy. Overall, the proportion of patients with at least one hemoglobin reading <120 g/L was 78%; <110 g/L, 54%; <100 g/L, 31%; and <90 g/L, 14%. Depending on chemotherapy type, a hemoglobin reading <100 g/L occurred in 5% to 54% of patients. Intervention rates increased as hemoglobin declined. For 99 patients with a hemoglobin reading <90 g/L, a discussion of anemia was documented in the treatment chart in 49% of cases, a transfusion was delivered in 23%, EPO was used in 11%, and transfusion and EPO were both delivered in 5%. Anemia was relatively common and varied with chemotherapy type. Documentation of a discussion of anemia occurred in fewer than 20% of the patients with a hemoglobin reading of 90–99 g/L and in only half the patients with a hemoglobin reading <90 g/L. Intervention rates were low at hemoglobin readings for which randomized trials have shown that intervention can improve quality of life.
- 1 December 2007
- Published by MDPI AG in Current Oncology
- Vol. 14 (6) , 227-233
Open AccessAnemia is a Common but Neglected Complication of Adjuvant Chemotherapy for Early Breast Cancer
In this study, we set out to determine the frequency and severity of anemia and the corrective interventions used during adjuvant chemotherapy for breast cancer. We conducted a retrospective electronic chart review of 702 patients who received adjuvant breast cancer chemotherapy at four BC Cancer Agency centres in 2002 and 2003. For these patients, we recorded the initial hemoglobin reading and the date of the first hemoglobin reading in the ranges 110–119 g/L, 100– 109 g/L, 90–99 g/L, and <90 g/L. We also recorded any discussion about, or delivery of, interventions for anemia [transfusion, epoetin (EPO) or both]. Median age of the study population was 51 years, and it varied with chemotherapy type. Among the patients, 12% had a hemoglobin reading <120 g/L before the start of chemotherapy. Overall, the proportion of patients with at least one hemoglobin reading <120 g/L was 78%; <110 g/L, 54%; <100 g/L, 31%; and <90 g/L, 14%. Depending on chemotherapy type, a hemoglobin reading <100 g/L occurred in 5% to 54% of patients. Intervention rates increased as hemoglobin declined. For 99 patients with a hemoglobin reading <90 g/L, a discussion of anemia was documented in the treatment chart in 49% of cases, a transfusion was delivered in 23%, EPO was used in 11%, and transfusion and EPO were both delivered in 5%. Anemia was relatively common and varied with chemotherapy type. Documentation of a discussion of anemia occurred in fewer than 20% of the patients with a hemoglobin reading of 90–99 g/L and in only half the patients with a hemoglobin reading <90 g/L. Intervention rates were low at hemoglobin readings for which randomized trials have shown that intervention can improve quality of life.
- 20 April 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (12) , 2716-2725
Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
Purpose Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. Methods Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer–specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared. Results Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted − observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted − observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different. Conclusion Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.
- 20 April 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (12) , 2716-2725
Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
Purpose Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. Methods Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer–specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared. Results Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted − observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted − observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different. Conclusion Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.
- 7 January 2004
- Published by Hindawi Limited in The Breast Journal
- Vol. 10 (1) , 38-44
Increased Use of Adjuvant Regional Radiotherapy for Node-Positive Breast Cancer in British Columbia
This study was to determine if the use of regional radiotherapy (RT) changed in British Columbia after publication of new randomized trial data in 1997. Women with pathologic T1–3N1, nonmetastatic breast cancer treated with a mastectomy or breast‐conserving surgery (BCS) were included. The use of regional RT was compared in two cohorts: cohort 1, July 1, 1995–June 30, 1997 (n = 834); and cohort 2, July 1, 1998–June 30, 2000 (n = 1072). All p‐values were two‐sided. Adjuvant systemic therapy was given to 96% and 95% of women in cohorts 1 and 2, respectively. Forty‐five percent of cohort 1 and 48% of cohort 2 had BCS. Regional RT was received by 44% of cohort 1 and 66% of cohort 2 (p < 0.001). Eighty‐eight percent and 90% of women with four or more positive nodes in cohorts 1 and 2 received regional RT, respectively. For women in cohorts 1 and 2 with one to three positive nodes, regional RT use increased from 32% to 54% after mastectomy, and from 23% to 59% after BCS, respectively (p < 0.001 for both). Publication of randomized trials and a coordinated guideline implementation process in British Columbia was associated with a significant increase in the use of regional RT in women with one to three positive nodes.
- 7 January 2004
- Published by Hindawi Limited in The Breast Journal
- Vol. 10 (1) , 38-44
Increased Use of Adjuvant Regional Radiotherapy for Node-Positive Breast Cancer in British Columbia
This study was to determine if the use of regional radiotherapy (RT) changed in British Columbia after publication of new randomized trial data in 1997. Women with pathologic T1–3N1, nonmetastatic breast cancer treated with a mastectomy or breast‐conserving surgery (BCS) were included. The use of regional RT was compared in two cohorts: cohort 1, July 1, 1995–June 30, 1997 (n = 834); and cohort 2, July 1, 1998–June 30, 2000 (n = 1072). All p‐values were two‐sided. Adjuvant systemic therapy was given to 96% and 95% of women in cohorts 1 and 2, respectively. Forty‐five percent of cohort 1 and 48% of cohort 2 had BCS. Regional RT was received by 44% of cohort 1 and 66% of cohort 2 (p < 0.001). Eighty‐eight percent and 90% of women with four or more positive nodes in cohorts 1 and 2 received regional RT, respectively. For women in cohorts 1 and 2 with one to three positive nodes, regional RT use increased from 32% to 54% after mastectomy, and from 23% to 59% after BCS, respectively (p < 0.001 for both). Publication of randomized trials and a coordinated guideline implementation process in British Columbia was associated with a significant increase in the use of regional RT in women with one to three positive nodes.
- 1 December 2003
- Published by Elsevier in Clinical Breast Cancer
- Vol. 4 (5) , 361-363
A Clinical Trial of Breast Radiation Therapy Versus Breast and Regional Radiation Therapy in Early-Stage Breast Cancer: The MA20 Trial
- 1 December 2003
- Published by Elsevier in Clinical Breast Cancer
- Vol. 4 (5) , 361-363
A Clinical Trial of Breast Radiation Therapy Versus Breast and Regional Radiation Therapy in Early-Stage Breast Cancer: The MA20 Trial
- 1 August 2003
- Vol. 46 (4) , 273-8
Practice patterns of lymph-node mapping and sentinel-node biopsy for breast cancer in British Columbia.
Because there is no standardized technique for mapping of lymph nodes and no optimal technique for evaluating the sentinel node, we decided to evaluate practice patterns for sentinel-node biopsy (SNB) for breast cancer in British Columbia 5 years after its introduction in 1996. We carried out mail and telephone surveys of general surgeons performing at least 1 SNB (n = 28) or not performing SNB (n = 50), and carried out telephone surveys or on-site visits with pathologists (n = 7) and nuclear medicine physicians (n = 5) from institutions supporting SNB in the province. We collected data on training, perceived indications and techniques for the surgical, imaging and pathologic assessments of SNB to obtain data on practice patterns in 2001 and the degree of consistency among surgeons and institutions involved in performing SNB and reasons for not adopting the SNB technique. By 2001, SNB was incorporated into the practice of 19% of surgeons (28 of 150) performing breast cancer surgery in British Columbia. The survey response rate among SNB surgeons was 89% (25 of 28). Twelve (48%) of the 25 surgeons implemented SNB in the context of a validation study. Ten (40%) of the 25 had no data management support to monitor their results. Surgical training included intraoperative mentoring alone (48%), formal training courses alone (20%), both (24%) and self-teaching (8%). One-third of the surgeons had performed fewer than 10 procedures. Five surgeons had abandoned routine axillary dissection. There was considerable variation regarding the indications for SNB, definition of a sentinel node and surgical techniques. All nuclear medicine departments had a written lymphatic mapping protocol, but each used a different volume and activity of radiotracer. Immunohistochemical evaluation of the sentinel nodes was performed at just 3 pathology laboratories. The survey response rate from surgeons not practising SNB was 54% (27 of 50). Among 24 responders in active practice, 7 (29%) planned to perform SNB; 79% had not decided on the SNB indications. Lack of operating room time was a major limiting factor. There was considerable variation in the surgical, nuclear medicine and pathology techniques for SNB in the absence of a planned approach for its implementation in British Columbia. Developing consensus around written guidelines for the indications and techniques of SNB may reduce this variation.
- 1 August 2003
- Vol. 46 (4) , 273-8
Practice patterns of lymph-node mapping and sentinel-node biopsy for breast cancer in British Columbia.
Because there is no standardized technique for mapping of lymph nodes and no optimal technique for evaluating the sentinel node, we decided to evaluate practice patterns for sentinel-node biopsy (SNB) for breast cancer in British Columbia 5 years after its introduction in 1996. We carried out mail and telephone surveys of general surgeons performing at least 1 SNB (n = 28) or not performing SNB (n = 50), and carried out telephone surveys or on-site visits with pathologists (n = 7) and nuclear medicine physicians (n = 5) from institutions supporting SNB in the province. We collected data on training, perceived indications and techniques for the surgical, imaging and pathologic assessments of SNB to obtain data on practice patterns in 2001 and the degree of consistency among surgeons and institutions involved in performing SNB and reasons for not adopting the SNB technique. By 2001, SNB was incorporated into the practice of 19% of surgeons (28 of 150) performing breast cancer surgery in British Columbia. The survey response rate among SNB surgeons was 89% (25 of 28). Twelve (48%) of the 25 surgeons implemented SNB in the context of a validation study. Ten (40%) of the 25 had no data management support to monitor their results. Surgical training included intraoperative mentoring alone (48%), formal training courses alone (20%), both (24%) and self-teaching (8%). One-third of the surgeons had performed fewer than 10 procedures. Five surgeons had abandoned routine axillary dissection. There was considerable variation regarding the indications for SNB, definition of a sentinel node and surgical techniques. All nuclear medicine departments had a written lymphatic mapping protocol, but each used a different volume and activity of radiotracer. Immunohistochemical evaluation of the sentinel nodes was performed at just 3 pathology laboratories. The survey response rate from surgeons not practising SNB was 54% (27 of 50). Among 24 responders in active practice, 7 (29%) planned to perform SNB; 79% had not decided on the SNB indications. Lack of operating room time was a major limiting factor. There was considerable variation in the surgical, nuclear medicine and pathology techniques for SNB in the absence of a planned approach for its implementation in British Columbia. Developing consensus around written guidelines for the indications and techniques of SNB may reduce this variation.
- 1 March 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (5) , 851-854
Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer
Background: Patients with supraclavicular metastases at diagnosis of breast cancer were classified between 1987 and 2002 as having stage M1 breast cancer according to the tumor-node-metastasis (TNM) system. The 2003 edition of the TNM staging guidelines has classified such patients as having stage IIIC disease. To determine relative prognosis, we compared long-term survival in a population-based cohort of patients with isolated supraclavicular metastases (nodal-M1) to outcomes of patients with stage IIIB or M1 (other) disease at presentation. Materials and Methods: Among patients with breast cancer and known tumor stage referred to the British Columbia Cancer Agency from 1976 to 1985, 336 IIIB, 233 M1, and 51 nodal-M1 patients were identified. Actuarial overall and breast cancer–specific survival rates were determined to 20 years. Results: Overall survival at 20 years was 13.2% for nodal-M1 cases (95% confidence interval [CI], 5% to 26%), 9.4% for IIIB cases (95% CI, 6% to 14%), and 1.3% for M1 (other) cases (95% CI, 0.4% to 3.5%; log-rank P < .0005). Overall survival was similar between nodal-M1 and IIIB cases (P = .27). Breast cancer–specific survival at 20 years was 24.1% for nodal-M1 cases (95% CI, 13% to 37%), 30.2% for IIIB cases (95% CI, 23% to 38%), and 3.9% for M1 (other) cases (95% CI, 2% to 8%; log-rank P < .0005). Breast cancer–specific survival was significantly different for nodal-M1 cases compared with either IIIB or M1 (other) cases (P = .008 for both). Conclusion: Patients with supraclavicular metastases at diagnosis have significantly better outcomes than patients with M1 (other) disease and overall survival similar to patients with IIIB disease. Reclassification as stage IIIC is appropriate for patients with breast cancer who present with supraclavicular nodal metastases alone.
- 1 March 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (5) , 851-854
Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer
Background: Patients with supraclavicular metastases at diagnosis of breast cancer were classified between 1987 and 2002 as having stage M1 breast cancer according to the tumor-node-metastasis (TNM) system. The 2003 edition of the TNM staging guidelines has classified such patients as having stage IIIC disease. To determine relative prognosis, we compared long-term survival in a population-based cohort of patients with isolated supraclavicular metastases (nodal-M1) to outcomes of patients with stage IIIB or M1 (other) disease at presentation. Materials and Methods: Among patients with breast cancer and known tumor stage referred to the British Columbia Cancer Agency from 1976 to 1985, 336 IIIB, 233 M1, and 51 nodal-M1 patients were identified. Actuarial overall and breast cancer–specific survival rates were determined to 20 years. Results: Overall survival at 20 years was 13.2% for nodal-M1 cases (95% confidence interval [CI], 5% to 26%), 9.4% for IIIB cases (95% CI, 6% to 14%), and 1.3% for M1 (other) cases (95% CI, 0.4% to 3.5%; log-rank P < .0005). Overall survival was similar between nodal-M1 and IIIB cases (P = .27). Breast cancer–specific survival at 20 years was 24.1% for nodal-M1 cases (95% CI, 13% to 37%), 30.2% for IIIB cases (95% CI, 23% to 38%), and 3.9% for M1 (other) cases (95% CI, 2% to 8%; log-rank P < .0005). Breast cancer–specific survival was significantly different for nodal-M1 cases compared with either IIIB or M1 (other) cases (P = .008 for both). Conclusion: Patients with supraclavicular metastases at diagnosis have significantly better outcomes than patients with M1 (other) disease and overall survival similar to patients with IIIB disease. Reclassification as stage IIIC is appropriate for patients with breast cancer who present with supraclavicular nodal metastases alone.
- Open Access
- 1 September 2000
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 7 (3) , 152-159
Ten years of breast screening in the Screening Mammography Program of British Columbia, 1988–97
Objectives To evaluate 10 year outcomes of the Screening Mammography Program of British Columbia (SMPBC) and determine if breast screening targets were being achieved among women aged 40–80+ years. Setting Organised breast screening programme in British Columbia, Canada. Methods Rates of participation, abnormal referral, cancer detection, and interval cancer were calculated for asymptomatic women receiving an SMPBC mammography from 1988–97. Results 895 849 screening mammographies were provided to 335 433 women. 51.3% of women were age 50–69 years. Abnormalities were identified on 57 454 screens (6.4%) from which 3304 cancers were detected. Abnormal call rates were higher on first (9.8%), compared with subsequent screens (4.4%) and declined with age: 7.7% at age < 40 to 5.4% for age 70–79 years. Cancer detection rates were higher on first (5.0 per 1000) compared with subsequent screens (2.8 per 1000) and increased smoothly with age from 1.4 to 8.2 per 1000 from age < 40 to age 80 years and older. Twenty per cent of cancers were non-invasive. The median size of invasive cancers was 14 mm and 81% had no axillary lymph node metastases. The 12 month interval cancer rate was 0.6 per 1000 and did not vary significantly with age or screening history. The prevalence to expected incidence ratio was 3.1 for women age 50–79 years. Conclusion Across a broad range of ages, surrogate indices of screening mammography success have been achieved in a population based, North American, organised breast cancer screening programme.
- 1 September 2000
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 7 (3) , 152-159
Open AccessTen years of breast screening in the Screening Mammography Program of British Columbia, 1988–97
Objectives To evaluate 10 year outcomes of the Screening Mammography Program of British Columbia (SMPBC) and determine if breast screening targets were being achieved among women aged 40–80+ years. Setting Organised breast screening programme in British Columbia, Canada. Methods Rates of participation, abnormal referral, cancer detection, and interval cancer were calculated for asymptomatic women receiving an SMPBC mammography from 1988–97. Results 895 849 screening mammographies were provided to 335 433 women. 51.3% of women were age 50–69 years. Abnormalities were identified on 57 454 screens (6.4%) from which 3304 cancers were detected. Abnormal call rates were higher on first (9.8%), compared with subsequent screens (4.4%) and declined with age: 7.7% at age < 40 to 5.4% for age 70–79 years. Cancer detection rates were higher on first (5.0 per 1000) compared with subsequent screens (2.8 per 1000) and increased smoothly with age from 1.4 to 8.2 per 1000 from age < 40 to age 80 years and older. Twenty per cent of cancers were non-invasive. The median size of invasive cancers was 14 mm and 81% had no axillary lymph node metastases. The 12 month interval cancer rate was 0.6 per 1000 and did not vary significantly with age or screening history. The prevalence to expected incidence ratio was 3.1 for women age 50–79 years. Conclusion Across a broad range of ages, surrogate indices of screening mammography success have been achieved in a population based, North American, organised breast cancer screening programme.
- 1 March 2000
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 91 (2) , 113-117
Waiting for a Diagnosis After an Abnormal Screening Mammogram
Background: Women with abnormal screening mammograms require diagnostic assessment and experience anxiety until a diagnosis is established. This report evaluated the timeliness of diagnosis after an abnormal screening mammogram in the Screening Mammography Program of British Columbia (SMPBC). Methods: Information on diagnostic interventions following an abnormal screen (N = 10,314) provided through 11 regional SMPBC services between January 1, 1993 and June 30, 1994 were abstracted and analyzed. Results: The median time from abnormal screen to diagnosis was 3.4 weeks with regional variation of 2.0 to 4.7 weeks; 10% waited 8.7 weeks or longer. For the 19% of women proceeding to open biopsy, the median diagnostic interval was 7.1 weeks with regional variation of 4.6 to 9.3 weeks; 10% waited 13.1 weeks or longer. Interpretation: After an abnormal screening mammogram, women waited many weeks for a definitive diagnosis, especially those proceeding to open biopsy. Opportunities for process improvement were identified. Contexte: Les femmes qui ont une mammographie anormale et qui nécessitent une évaluation diagnostique, vivent dans l’anxiété jusqu’à la confirmation du diagnostic. Ce rapport a cherché à évaluer les délais d’attente du diagnostic après une mammographie anormale dans le cadre du programme de dépistage par mammographie de la Colombie-Britannique (Screening Mammography Program of British Columbia ou SMPBC). Méthodologie: Les données relatives aux interventions diagnostiques suite à une mammographie anormale (N = 10 314) provenant de 11 services régionaux faisant partie du Programme, et couvrant la période du 1er janvier 1993 au 30 juin 1994, ont été analysées. Résultats: L’intervalle moyen entre la mammographie et la pose du diagnostic était de 3,4 semaines, avec des variations régionales de 2 à 4,7 semaines; 10 % des femmes ont dû attendre 8,7 semaines ou plus. Pour les 19 % sur lesquelles on a procédé à une biopsie, l’intervalle de temps avant le diagnostic était de 7,1 semaines, avec des variations régionales de 4,6 à 9,3 semaines; 10 % des femmes ont dû attendre 13,1 semaines ou plus. Interprétation: Après une mammographie anormale, les femmes ont dû attendre de nombreuses semaines avant d’avoir un diagnostic définitif, notamment dans le cas de celles ayant eu une biopsie. Nous avons identifié un certain nombre de secteurs qui permettraient d’améliorer la procédure.
- 1 March 2000
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 91 (2) , 113-117
Waiting for a Diagnosis After an Abnormal Screening Mammogram
Background: Women with abnormal screening mammograms require diagnostic assessment and experience anxiety until a diagnosis is established. This report evaluated the timeliness of diagnosis after an abnormal screening mammogram in the Screening Mammography Program of British Columbia (SMPBC). Methods: Information on diagnostic interventions following an abnormal screen (N = 10,314) provided through 11 regional SMPBC services between January 1, 1993 and June 30, 1994 were abstracted and analyzed. Results: The median time from abnormal screen to diagnosis was 3.4 weeks with regional variation of 2.0 to 4.7 weeks; 10% waited 8.7 weeks or longer. For the 19% of women proceeding to open biopsy, the median diagnostic interval was 7.1 weeks with regional variation of 4.6 to 9.3 weeks; 10% waited 13.1 weeks or longer. Interpretation: After an abnormal screening mammogram, women waited many weeks for a definitive diagnosis, especially those proceeding to open biopsy. Opportunities for process improvement were identified. Contexte: Les femmes qui ont une mammographie anormale et qui nécessitent une évaluation diagnostique, vivent dans l’anxiété jusqu’à la confirmation du diagnostic. Ce rapport a cherché à évaluer les délais d’attente du diagnostic après une mammographie anormale dans le cadre du programme de dépistage par mammographie de la Colombie-Britannique (Screening Mammography Program of British Columbia ou SMPBC). Méthodologie: Les données relatives aux interventions diagnostiques suite à une mammographie anormale (N = 10 314) provenant de 11 services régionaux faisant partie du Programme, et couvrant la période du 1er janvier 1993 au 30 juin 1994, ont été analysées. Résultats: L’intervalle moyen entre la mammographie et la pose du diagnostic était de 3,4 semaines, avec des variations régionales de 2 à 4,7 semaines; 10 % des femmes ont dû attendre 8,7 semaines ou plus. Pour les 19 % sur lesquelles on a procédé à une biopsie, l’intervalle de temps avant le diagnostic était de 7,1 semaines, avec des variations régionales de 4,6 à 9,3 semaines; 10 % des femmes ont dû attendre 13,1 semaines ou plus. Interprétation: Après une mammographie anormale, les femmes ont dû attendre de nombreuses semaines avant d’avoir un diagnostic définitif, notamment dans le cas de celles ayant eu une biopsie. Nous avons identifié un certain nombre de secteurs qui permettraient d’améliorer la procédure.